Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations - PubMed (original) (raw)
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations
R P Zweemer et al. Gynecol Oncol. 2000 Jan.
Abstract
Objectives: BRCA1 and BRCA2 germline mutations increase the risk of ovarian and breast cancer. Fallopian tube cancer has occasionally been observed in breast-ovarian cancer families. At our family cancer clinic we recently encountered two cases of Fallopian tube cancer within two families harboring a BRCA1 germline mutation. To study the relationship between Fallopian tube cancer and BRCA1 mutations, a histopathological reevaluation and molecular analysis were performed.
Methods: Medical and histopathological reports of the Fallopian tube cancer cases as well as archival tissue blocks were retrieved. The histopathological diagnoses were reevaluated. We investigated whether patients with Fallopian tube cancer had been carriers of a BRCA germline mutation. In addition we investigated whether loss of the wild-type allele had occurred in the tumor.
Results: In 2 of 23 families with a known BRCA1 mutation from our family cancer clinic, a case of Fallopian tube cancer was reported. Histological reevaluation confirmed the diagnosis of Fallopian tube cancer in both cases. In one case Fallopian tube cancer may have been part of a multifocal primary malignancy. In both patients the presence of a BRCA1 mutation was confirmed in the germline. Furthermore, we showed loss of the wild-type BRCA1 allele in both tumors.
Conclusions: These findings provide the first molecular evidence that Fallopian tube cancer may be due to germline mutations in BRCA1. This may have important consequences for the preferred method of prophylactic oophorectomy in BRCA1 mutation carriers.
Copyright 2000 Academic Press.
Comment in
- Fallopian tube cancer as a feature of BRCA1-associated syndromes.
Sobol H, Jacquemier J, Bonaiti C, Dauplat J, Birnbaum D, Eisinger F. Sobol H, et al. Gynecol Oncol. 2000 Aug;78(2):263-4. doi: 10.1006/gyno.2000.5897. Gynecol Oncol. 2000. PMID: 10926816 No abstract available. - Occult cancer in the fallopian tube in patients with a BRCA-1 germline mutation.
Ansink AC, Burger CW, Seynaeve C. Ansink AC, et al. Gynecol Oncol. 2001 Nov;83(2):445. doi: 10.1006/gyno.2001.6290. Gynecol Oncol. 2001. PMID: 11606115 No abstract available.
Similar articles
- Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA. Paley PJ, et al. Gynecol Oncol. 2001 Feb;80(2):176-80. doi: 10.1006/gyno.2000.6071. Gynecol Oncol. 2001. PMID: 11161856 - BRCA2 germline mutations in primary cancer of the fallopian tube.
Casarsa S, Puglisi F, Baudi F, De Paola L, Venuta S, Piga A, Di Loreto C, Marchesoni D, D'Elia AV, Damante G. Casarsa S, et al. Oncol Rep. 2004 Aug;12(2):313-6. Oncol Rep. 2004. PMID: 15254695 - Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Vicus D, et al. Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10. Gynecol Oncol. 2010. PMID: 20452659 - Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Casey MJ, et al. Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review. - Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B, Lux MP, Goecke TO, Beckmann MW. Kuschel B, et al. Eur J Cancer Prev. 2000 Jun;9(3):139-50. Eur J Cancer Prev. 2000. PMID: 10954253 Review.
Cited by
- Organoid modeling meets cancers of female reproductive tract.
Li J, Zhou M, Xie J, Chen J, Yang M, Ye C, Cheng S, Liu M, Li R, Tan R. Li J, et al. Cell Death Discov. 2024 Sep 27;10(1):410. doi: 10.1038/s41420-024-02186-x. Cell Death Discov. 2024. PMID: 39333482 Free PMC article. Review. - Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells.
Reavis HD, Gysler SM, McKenney GB, Knarr M, Lusk HJ, Rawat P, Rendulich HS, Mitchell MA, Berger DS, Moon JS, Ryu S, Mainigi M, Iwanicki MP, Hoon DS, Sanchez LM, Drapkin R. Reavis HD, et al. JCI Insight. 2024 Mar 8;9(5):e170961. doi: 10.1172/jci.insight.170961. JCI Insight. 2024. PMID: 38271085 Free PMC article. - Surgical Management of Hereditary Breast Cancer.
Berger ER, Golshan M. Berger ER, et al. Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371. Genes (Basel). 2021. PMID: 34573353 Free PMC article. Review. - Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.
Hart PC, Bajwa P, Kenny HA. Hart PC, et al. Adv Exp Med Biol. 2021;1330:75-94. doi: 10.1007/978-3-030-73359-9_5. Adv Exp Med Biol. 2021. PMID: 34339031 Review. - Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
Boerner T, Walch HS, Nguyen B, Iasonos A, Zhou QC, Schultz N, Chui MH, Grisham RN, Tew WP, O'Cearbhaill RE, Aghajanian C, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, Chi DS, Long Roche K. Boerner T, et al. Gynecol Oncol. 2021 Mar;160(3):696-703. doi: 10.1016/j.ygyno.2020.12.022. Epub 2020 Dec 30. Gynecol Oncol. 2021. PMID: 33386131 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous